HALIFAX, NS / ACCESS Newswire / June 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025.Corporate updateIn Q3 FY2025, MedMira ...

Funding Shortfalls Pressure Small and Rural Hospitals to Delay Essential Data Security Investments; Survey of 187 Small ...

Compass Pathways has announced that its investigational psilocybin therapy, COMP360, met the primary endpoint in its Phase 3 ...

Annual General Meeting GUILDFORD, SURREY / ACCESS Newswire / June 30, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of ...

WASHINGTON, DC / ACCESS Newswire / June 30, 2025 / The not-for-profit Aimed Alliance released a comprehensive new report analyzing how state policies govern step therapy, internal and external appeal ...

TURKU, FINLAND / ACCESS Newswire / June 30, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, ...

PRO isn’t just digitized data collection. It’s real-time, structured, regulatory-grade intelligence, designed to enhance compliance, cut down queries, and keep patients engaged.Despite operating in a ...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPFirst-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy ...

CD Genomics has launched its innovative EM-seq Service, a major advancement in sequencing technology that enhances the accuracy and efficiency of genetic analysis. This new service highlights CD ...

Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA ...

A New Perspective on Addiction RecoveryIn the journey to overcome addiction, one size certainly does not fit all. Every individual faces different challenges, circumstances, and needs. While some ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...